|
1
|
Soltani A, Fatollahzadeh M, Izadi P, Rad ZA, Tavassol ZH, Pajavand H, Amini M, Hasani-Ranjbar S. Estrogen-insensitivity syndrome (EIS) in a female adolescent patient - a case report. J Pediatr Endocrinol Metab 2024; 37:990-994. [PMID: 39295121 DOI: 10.1515/jpem-2024-0176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2024] [Accepted: 09/04/2024] [Indexed: 09/21/2024]
Abstract
OBJECTIVES Estrogen insensitivity syndrome (EIS) is a rare genetic disorder characterized by an autosomal dominant inheritance pattern. The disease results from a pathogenic variant in the ESR1 (estrogen receptor 1) gene, leading to estrogen resistance in individuals possessing the 46, XX karyotype. The alpha receptor, which is predominant in peripheral tissues, is responsible for estrogen action. As a result, pathogenic variants in the ESR1 gene can cause various disorders, such as changes in secondary sexual characteristics, increased concentrations of estrogen and gonadotropins, and delayed bone maturation. CASE PRESENTATION Here, the case of a 13-year-old girl, with high estrogen and gonadotropin concentrations, lack of breast development, uterine growth and delayed bone age is described. The patient's parents were related. She was found to have a homozygous pathogenic variant in the ESR1 gene located on chromosome 6q25, which interferes with estrogen signaling. CONCLUSIONS This case supports that disruption of ESR1 causes profound estrogen resistance in females.
Collapse
Affiliation(s)
- Akbar Soltani
- Evidence Based Medicine Research Center, 48439 Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran, Iran
| | - Mahdieh Fatollahzadeh
- Evidence Based Medicine Research Center, 48439 Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran, Iran
| | - Pantea Izadi
- Department of Medical Genetics, School of Medicine, 48439 Tehran University of Medical Sciences , Tehran, Iran
| | - Zahra Abbaspour Rad
- Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
| | - Zahra Hoseini Tavassol
- Obesity and Eating Habits Research Center, 48439 Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran, Iran
| | - Hamid Pajavand
- Evidence Based Medicine Research Center, 48439 Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran, Iran
| | - Masoomeh Amini
- Department of Medical Genetics, School of Medicine, 48439 Tehran University of Medical Sciences , Tehran, Iran
| | - Shirin Hasani-Ranjbar
- Obesity and Eating Habits Research Center, 48439 Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran, Iran
| |
Collapse
|
|
2
|
Shibasaki I, Nakajima T, Fukuda T, Hasegawa T, Ogawa H, Tsuchiya G, Takei Y, Tezuka M, Kato T, Kanazawa Y, Kano Y, Kuwata T, Ouchi M, Toyoda S, Aso Y, Fukuda H. Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors. J Clin Med 2022; 11:jcm11154333. [PMID: 35893426 PMCID: PMC9331841 DOI: 10.3390/jcm11154333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 07/18/2022] [Accepted: 07/22/2022] [Indexed: 12/25/2022] Open
Abstract
Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 levels in SAT and EAT with and without DPP-4 inhibitors. This study included 40 patients (25 men, age 67.5 ± 13.8 years). The serum adipokine, DPP-4, and adiponectin levels in SAT and EAT were measured using ELISA and Western blotting. The DPP-4 and adiponectin levels were significantly higher in the SAT than in the EAT. The serum DPP-4 and DPP-4 activity levels had no correlation with the DPP-4 levels in the SAT and EAT, but the DPP-4 levels in the SAT and EAT had a positive correlation. The DPP-4 levels in the SAT were positively correlated with atherosclerosis, diabetes mellitus, DPP-4-inhibitor use, and fasting blood glucose. The DPP-4 levels in the EAT showed a negative correlation with eGFR and a positive correlation with atrial fibrillation. The DPP-4 activity in the serum had a lower tendency in the group taking DPP-4 inhibitors than in the group not taking them. DPP-4 inhibitors may suppress angiogenesis and adipose-tissue hypertrophy.
Collapse
Affiliation(s)
- Ikuko Shibasaki
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
- Correspondence:
| | - Toshiaki Nakajima
- Department of Medical KAATSU Training, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (T.N.); (T.H.)
- Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan;
| | - Taira Fukuda
- Department of Liberal Arts and Human Development, Kanagawa University of Human Services, Yokosuka 238-8522, Kanagawa, Japan;
| | - Takaaki Hasegawa
- Department of Medical KAATSU Training, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (T.N.); (T.H.)
| | - Hironaga Ogawa
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Go Tsuchiya
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Yusuke Takei
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Masahiro Tezuka
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Takashi Kato
- Department of Cardiovascular Surgery, Maebashi Red Cross Hospital, Maebashi 371-0811, Gunma, Japan; (T.K.); (T.K.)
| | - Yuta Kanazawa
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Yasuyuki Kano
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| | - Toshiyuki Kuwata
- Department of Cardiovascular Surgery, Maebashi Red Cross Hospital, Maebashi 371-0811, Gunma, Japan; (T.K.); (T.K.)
| | - Motoshi Ouchi
- Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan;
| | - Shigeru Toyoda
- Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan;
| | - Yoshimasa Aso
- Department of Endocrinology and Metabolism, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan;
| | - Hirotsugu Fukuda
- Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan; (H.O.); (G.T.); (Y.T.); (M.T.); (Y.K.); (Y.K.); (H.F.)
| |
Collapse
|